Staphylococcal alpha-toxin tilts the balance between malignant and non-malignant CD4+ T cells in cutaneous T-cell lymphoma

Oncoimmunology. 2019 Jul 17;8(11):e1641387. doi: 10.1080/2162402X.2019.1641387. eCollection 2019.

Abstract

Staphylococcus aureus is implicated in disease progression in cutaneous T-cell lymphoma (CTCL). Here, we demonstrate that malignant T cell lines derived from CTCL patients as well as primary malignant CD4+ T cells from Sézary syndrome patients are considerably more resistant to alpha-toxin-induced cell death than their non-malignant counterparts. Thus, in a subset of Sézary syndrome patients the ratio between malignant and non-malignant CD4+ T cells increases significantly following exposure to alpha-toxin. Whereas toxin-induced cell death is ADAM10 dependent in healthy CD4+ T cells, resistance to alpha-toxin in malignant T cells involves both downregulation of ADAM10 as well as other resistance mechanisms. In conclusion, we provide first evidence that Staphylococcus aureus derived alpha-toxin can tilt the balance between malignant and non-malignant CD4+ T cells in CTCL patients. Consequently, alpha-toxin may promote disease progression through positive selection of malignant CD4+ T cells, identifying alpha-toxin as a putative drug target in CTCL.

Keywords: Cutaneous T-cell lymphoma; Staphylococcus aureus; alpha-toxin; disintegrin and metalloproteinase domain-containing protein 10.

Publication types

  • Research Support, Non-U.S. Gov't

Grants and funding

This work was supported by a donation from the LEO Foundation and grants from The Novo Nordisk Research Foundation (NNF14OC0012345), the Danish Cancer Society (Kræftens Bekæmpelse), the Fight Cancer Program (Knæk Cancer), and the Lundbeck Foundation.